Faison, Shamia L.
Batonga, Joelle
Arumugham, Thangam
Bartkus, Angela
Morrison, Marion E.
Mullin, Mark J.
Tippin, Tim
Naderer, Odin https://orcid.org/0009-0002-0809-274X
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effect of Severe Renal Impairment on Dordaviprone (ONC201) Pharmacokinetics
https://doi.org/10.1007/s40268-025-00520-x
Article History
Accepted: 17 July 2025
First Online: 30 July 2025
Declarations
:
: Angela Bartkus, Marion E. Morrison, Mark J. Mullin, Tim Tippin, and Odin Naderer are employees of Chimerix, Inc. and hold stock in Chimerix, Inc.; Shamia L. Faison and Joelle Batonga are paid consultants of Chimerix, Inc. Thangam Arumugham is a paid consultant of and holds stock in Chimerix, Inc.
: Subject-level data collected as part of this study are not available for analysis by independent researchers.
: Code used for this analysis is not available to independent researchers.
: This study was conducted in accordance with the protocol and consensus ethical principles derived from international guidelines including the Declaration of Helsinki, Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines, and other applicable laws and regulations. The protocol, protocol amendments, informed consent forms, Investigator Brochure, and other relevant documents (e.g., advertisements) were submitted to an independent ethics committee (IEC; Health and Disability Ethics Committees, Wellington, New Zealand) by the investigator and were reviewed and approved by the IEC before the study was initiated. Trial Registration Number, ACTRN12622000405718.
: Informed consent was obtained from all individual participants included in the study.
: Not applicable.